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1  |  INTRODUC TION
Antimicrobial	 resistance	 is	 a	 growing	 problem,	 widely	 recognized	
as a major threat to public health.1-4 In general practice, there is a 
major	concern	that	some	common	infections	are	becoming	increas-
ingly	difficult	to	be	treated,	and	those	infections	caused	by	antibiot-
ic-resistant	bacteria	may	take	longer	to	be	resolved.5 Primary Care 
is	 responsible	 for	 most	 of	 the	 antibiotics	 prescriptions	 in	 human	
health.6-9	 There	 is	 a	 high	 prevalence	 of	 infectious	 diseases	 in	 this	
setting,10	and	two	thirds	of	patients	treated	for	infectious	diseases	
receive antibiotic therapy.2,6,7	This	 leads	to	25-30%	of	the	popula-
tion receiving antibiotics annually.11,12
Not	all	patients	 in	the	community	receive	the	same	burden	of	
antibiotics.13,14 While some patients receive antibiotics occasion-
ally, others receive antimicrobial treatments on a continuous or 
cyclic	manner	for	prolonged	periods	of	time,	 in	the	context	of	 in-
fectious	 diseases	 with	 indication	 of	 long-term	 treatments,	 recur-
rent	 infections	or	 for	prophylactic	purposes.13	These	patients	are	
more	susceptible	to	infections	by	multidrug	resistant	bacteria,15-17 
leading	 to	more	 frequent	 use	of	 broad-spectrum	antibiotics.	 This	
limits	the	possibility	of	treating	future	infections	in	the	ambulatory	
setting.18
Improving	 the	 appropriate	 use	 of	 antibiotics	 has	 become	 an	 in-
creasing	priority	for	Health	Services.	The	establishment	of	powerful	
interventions,	 preferably	 integrated	 into	 antimicrobial	 stewardship	













prescribing in these patients.




ting	 comprised	30	Healthcare	Areas	 from	12	of	 the	17	 regions	 in	
Spain	(Table	S1).	The	Spanish	National	Healthcare	System	is	organ-
ized	in	Health	Areas.	A	Health	Area	is	an	administrative	district	that	























penicillins	 (19%),	 or	 cephalosporins	 (12%).	Most	 frequently	 treated	 conditions	 were	
lower	 respiratory	 tract	 (infections	or	prophylaxis)	 (48%),	urinary	 (27%),	and	skin/soft	
tissue	infections	(11%).	Thirty-five	percent	have	been	guided	by	a	microbiological	diag-
nosis, being Pseudomonas aeruginosa	(30%)	and Escherichia coli	(16%)	the	most	frequent	
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The	unit	of	analysis	was	the	patient,	identified	by	the	use	of	his	
personal	social	insurance	system	card	number.	Inclusion	criteria	for	
high	 consumers	 were	 as	 follows:	 all	 patients	 assigned	 to	 Primary	
Care	centers	 from	the	study	areas,	having	at	 least	30	packages	of	
antibacterial	 agents	 for	 systemic	use	 (J01,	 according	 to	 the	WHO	
Anatomical	Therapeutic	Chemical	classification	system23)	dispensed	
from	January	to	December	2017.
2.2  |  Data sources and outcomes
Patients	 were	 identified	 through	 databases	 from	 computerized	
pharmacy	 records	 of	 reimbursed	 and	 dispensed	 drugs,	 from	 their	
Regional	 Health	 Care	 Services.	 Individual	 clinical	 data,	 diagnoses,	
and	 microbiological	 tests	 from	 patients	 were	 collected	 from	 the	
Electronic	medical	records	of	Public	Health	Services	maintained	for	
routine	 health-care	 activities.	 Diagnoses	 and	microbiological	 data	
were searched in consultation sheets, hospital admission or dis-
charge records, laboratory data applications, etc. Diagnoses were 












a numerical code. Data were stored securely in a data center with 
perimeter security.
The	 following	 variables,	 defined	 at	 the	 population	 level,	 were	













2.3  |  Statistical analysis
A	 descriptive	 analysis	 of	 the	 data	 was	 carried	 out	 to	 determine	
the	prevalence	and	profile	of	high	antibiotic	consumers.	Summary	





2.4  |  Ethics statement
This	research	was	conducted	in	accordance	with	the	Declaration	of	
Helsinki	and	national	and	institutional	legislation	in	Spain	regarding	
clinical research and personal data protection. It has been approved 
by	Hospitals	Virgen	del	Rocío	and	Virgen	Macarena	Ethics	Committee	
on	Health	Research	(Seville,	Spain)	 (Code	0295-N-18).	This	project	
is	 registered	 in	 the	 clinical	 studies	 database	of	 Spanish	Medicines	
Agency	and	Health	Products	(EPA-OD	code	GTI-ANT-2018-01).
3  |  RESULTS
3.1  |  Study population
We	have	 identified	 1,876,927	 patients	with	 antibiotics	 prescribed	
during	the	study	period.	The	prevalence	of	antibiotic	use	was	31%.	
Among	these	patients,	1,162	were	high	consumers	according	to	the	








pertension),	 neurological/mental,	 diabetes,	 urological	 disease,	 and	








ing agents, antidepressants, and antidiabetics.
3.2  |  Antibiotic treatments and infectious diseases
Patients	received	a	total	of	3,226	antibiotic	 treatments	during	the	
study	 period.	 Half	 of	 the	 patients	 (51%)	 received	 antibiotics	 for	
the	 entire	 annual	 period:	 24%	 received	 them	 in	 a	 single	 antibiotic	
course	and	76%	received	several	courses	(18%	received	two	courses;	
17%	 received	 three	 courses;	13%	 received	 four	 courses,	 and	28%	
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Peripheral arterial disease 51	(6) 4-8






Respiratory tract chronic conditions 553	(62) 59-65
Asthma 480	(54) 51-57







































Urological diseases 186	(21) 18-24
Chronic	renal	failure 109	(13) 10-15
Benign	prostate	hyperplasia 97	(11) 9-13

























Other immunosuppressive agents 72	(8) 6-10
Antipsychotics 71	(8) 6-10
Mucolytics 44	(5) 4-7
Cough suppressants 8	(1) 0-2














cephalosporins	 (Table	2).	When	analyzed	by	antibiotic	 agents,	 azi-




information	about	 the	 type	of	 infection	or	prophylaxis,	 and	2,786	
treatments	were	 linked	to	a	specific	diagnosis.	The	distribution	by	
site	of	infection	was	as	follows:
-	 48%	 of	 use	 for	 lower	 respiratory	 tract	 conditions	 (33%	 infec-
tions,	 12%	 prophylaxis),




Based	 on	 records,	 antibiotics	 were	 mainly	 used	 to	 treat	 in-
fections,	 with	 21%	 treatments	 used	 with	 prophylactic	 purposes.	
Prophylaxis	of	lower	respiratory	infections	accounted	for	69%	of	all	
established	prophylaxis.
Specific	 diagnosis	 for	 which	 antibiotics	 were	 used	 can	 be	 ob-




The	 distribution	 of	 antibiotics	 by	 condition	 is	 described	 in	
Figure 1.
Regarding	 the	 most	 widely	 used	 antibiotics:	 fluoroquinolones	
were	 the	 most	 prescribed	 in	 lower	 respiratory	 tract	 infections.	
They	were	also	frequently	prescribed	for	the	treatment	of	skin	and	
soft	 tissue	 infections,	upper	respiratory	tract	 infections,	and	UTIs.	
Macrolides	accounted	for	the	83%	of	the	of	lower	respiratory	tract	
infection	 prophylaxis,	 and	were	 also	 frequently	 used	 in	 the	 treat-
ment	of	upper	respiratory	tract	infections.	Fosfomycin	was	the	most	
widely	 used	 antibiotic	 in	 the	 treatment	 of	UTIs	 and	UTIs	 prophy-
laxis.	Penicillins	were	mainly	used	in	the	treatment	of	upper	respi-
ratory	 tract	 infections,	 skin	 and	 soft	 tissue	 infections,	 UTIs,	 and	
UTI	prophylaxis.	Finally,	cephalosporins	have	had	a	smaller	use	than	
previous groups, although we have stated a relative high use in the 
treatment	of	UTIs,	 lower	respiratory	tract	 infections,	and	skin	and	
soft	tissue	infections.
Clinicians who made the prescriptions were specialists in Family 
and	Community	Medicine	 (50%	of	 the	 total),	 followed	 by	 special-
ists	in	Pneumology	(25%),	Internal	Medicine	(8%),	and	Urology	(6%).	
These	four	professional	groups	accounted	for	88%	of	prescriptions.
3.3  |  Microbiological data
A	 total	 of	1,074	 samples	were	 recorded	 for	microbiological	 assess-
ment,	that	is,	35%	of	antibiotic	treatments	would	have	been	guided	
by	a	microbiological	diagnosis:	49%	corresponded	to	bronchial	exu-
dates,	 followed	 by	 urine	 cultures	 (32%),	 and	 skin	 exudates	 (13%)	
(Table	4).	In	84%	of	cases,	the	identification	of	one	or	several	etiologi-
cal agents was recorded. Pseudomonas aeruginosa	 (30%), Escherichia 
coli	(16%),	Staphylococcus aureus	(6%),	and	Klebsiella pneumoniae	(4%)	
TA B L E  2 Frequency	of	antibiotic	prescribing
Total
Number of antibiotic 
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were	 the	most	 frequent	 isolates.	According	 to	 the	 records,	 29%	of	





den	of	 antimicrobials	 in	 the	 community	 are,	basically,	 older	 adults	





rological and mental disorders, diabetes, malignancies, or chronic 
renal	 failure	were	more	 frequent	 than	 that	 reported	 for	 general	
population receiving antibiotics in the community.11,23 COPD and 
asthma	were	about	10	times	more	frequent	in	the	study	patients	
than in general population receiving antibiotics in the community 
Total
Number of antibiotic treatments linked 















Chronic bronchitis 80	(3) 2-3
Pneumonia 56	(2) 1-2
Other 80	(3) 2-3















Upper respiratory tract 
infections
126	(4) 3-5
Sore throat/pharyngotonsillitis 44	(1) 1-2







TA B L E  3 Conditions	treated	with	
antibiotics
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Lower respiratory tract infecons (n= 970)
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in Spain,11	and	the	prevalence	of	hypertension,	heart	diseases,	and	
diabetes was three times higher.11	 It	 should	 be	 emphasized	 the	
high	percentage	of	patients	with	chronic	renal	failure	among	high	
consumers	(12%).
Other aspects besides comorbidities such as smoking behavior, 
overweight/obesity, or polypharmacy, common conditions in pa-
tients in our study, might be associated with antibiotic prescribing 
decisions.	 In	 relation	 to	 concomitant	medication,	 PPI,	 NSAIDs,	 or	




prescribing than comorbidities themselves.13
Lower	 respiratory	 tract,	 urinary	 tract,	 and	 skin	 and	 soft	 tissue	
infections	or	prophylaxis	justified	most	antibiotic	treatments	in	high	
consumers.	However,	there	are	great	differences	between	the	con-
ditions in these patients and those treated in general population: 
antibiotic	use	for	the	treatment	of	exacerbations	of	COPD	and	bron-
chiectasis,	which	represent	a	2%	of	the	use	of	antibiotics	by	general	
population in the community,25	 accounted	 for	 34%	 of	 treatments	
in	high	consumers.	By	contrast,	upper	 respiratory	 tract	 infections,	
which	 represent	 the	 53%	 of	 infections	 treated	with	 antibiotics	 in	
the ambulatory setting,25	represented	a	4%	of	infections	treated	in	
















at the same time, this makes the patients increasingly susceptible to 
infections	by	multidrug-resistant	microorganisms.15,17 In addition, the 





tients received.12,27,28	 Rates	 of	 antibiotic	 prescribing	 to	 patients	
with	 asthma	 and	 COPD	 are	 1.6-	 and	 3-fold,	 respectively,	 higher	
than	 rates	 in	 general	 population,	 and	 patients	with	 heart	 failure,	
peripheral arterial disease, diabetes, or coronary artery disease are 
prescribed	47-69%	more	antibiotics	than	individuals	without	these	
conditions.12 Despite the great advances in the prevention, diagno-
sis,	and	treatment	of	 infectious	diseases,	these	continue	to	cause	




some patients with chronic diseases such as diabetes, COPD, heart 
failure,	or	those	with	multiple	pathologies.12,27,28-31	The	reason	for	
this	different	management	 lies	 in	 the	 tendency	of	 these	patients	
to	get	more	severe	and	recurrent	 infectious	diseases,	with	worse	
prognosis,	and	with	a	higher	probability	of	hospitalization	and	mor-
tality than in healthy people.12,28,31-34	 Nonetheless,	 unnecessary	
antibiotic	treatments,	excessively	long	treatments,	the	unjustified	
use	of	broad-spectrum	antibiotics,	or	injustified	prophylaxis	should	
be avoided in patients with comorbidities.
This	study	has	several	strengths.	First,	it	includes	a	large	repre-
sentative	 sample	of	 the	national	 territory,	 including	patients	of	 all	
ages	 cared	 by	 the	 Public	Health	Care	 Services	 for	 all	 possible	 di-
agnoses.	The	use	of	 individual	patients	as	 the	unit	of	 analysis	 is	 a	
major strength compared with studies conducted with aggregated 
data.	Full	information	about	patient’s	characteristics	and	underlying	
pathologies was collected. On the other hand, antibiotic prescrip-
tions	were	 linked	 to	clinical	 information	 in	96%	cases.	The	degree	
of	underregistration	of	diagnoses	 in	medical	 records	was	very	 low	
compared to other studies conducted in the Primary Care setting, 
which	reported	30-60%	diagnoses	unknown.25,35	All	this	enhances	
the	generalizability	of	the	results.
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Several	limitations	of	the	study	should	be	pointed	out.	First,	an-
tibiotic	prescribing	data	were	exclusively	collected	from	the	comput-
erized	pharmacy	 records	of	 dispensed	drugs	 from	Regional	 Public	
Health	Care	Services.	Hospital	inpatient	antibiotic	use,	private	med-
icine,	outpatient	parenteral	antibiotic	 therapy,	or	over-the-counter	
sales were not measured. Second, we were unable detect patient ad-




not	 accessed	 to	 hospital	 records.	 Information	 about	 other	 treat-
ments	or	infections	may	have	been	lost	for	not	being	registered	in	
Primary	Care	Digital	Health	History.
Our	 results	 have	 several	 implications	 for	 practice:	 (a)	 It	 is	
crucial	 that	antimicrobial	guides	 include	clear	 indications	 for	pa-
tients with chronic conditions, to avoid unnecessary treatments 
or	prophylaxis,	 to	adjust	 the	duration	of	 treatments	 to	 the	mini-
mum	effective,	and	to	reserve	broad-spectrum	antibiotics	to	cases	
of	 failure	or	 intolerance	 to	narrow-spectrum	antibiotics.	 (b)	ASP	
should	 consider	 specific	 interventions	 for	 patients	 with	 comor-
bidities	 and	 frequent	 infections,	 with	 a	 different	 approach	 than	
healthy	 patients.	 (c)	 Since	 professionals	 from	 both	 care	 settings	
(Primary	Care	and	Hospital)	are	involved	in	care	of	high	consum-









management	 from	 hospital	 care	 and	 frequent	 hospital	 admissions.	
Further studies should be addressed to determine whether high con-
sumers	are	prescribed	antibiotics	appropriately	or	whether	the	exces-
sive antibiotic use by these patients could be decreased or avoided.
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